Beck Mack & Oliver LLC cut its holdings in Grifols, S.A. (NASDAQ:GRFS) by 1.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,584,379 shares of the biotechnology company’s stock after selling 23,366 shares during the quarter. Beck Mack & Oliver LLC owned approximately 0.12% of Grifols, worth $34,682,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in GRFS. Ameriprise Financial Inc. lifted its stake in Grifols, by 16.1% in the first quarter. Ameriprise Financial Inc. now owns 13,277 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 1,839 shares during the period. Stifel Financial Corp lifted its stake in Grifols, by 4.3% in the first quarter. Stifel Financial Corp now owns 11,630 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 476 shares during the period. Geode Capital Management LLC lifted its stake in Grifols, by 49.3% in the first quarter. Geode Capital Management LLC now owns 103,591 shares of the biotechnology company’s stock worth $1,954,000 after acquiring an additional 34,193 shares during the period. Morgan Stanley lifted its stake in Grifols, by 20.2% in the first quarter. Morgan Stanley now owns 886,926 shares of the biotechnology company’s stock worth $16,741,000 after acquiring an additional 149,118 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Grifols, in the first quarter worth about $4,439,000. 21.93% of the stock is owned by institutional investors.
Grifols, S.A. (NASDAQ:GRFS) traded up 3.88% during mid-day trading on Tuesday, reaching $23.32. 696,170 shares of the company were exchanged. The stock has a market capitalization of $31.87 billion, a price-to-earnings ratio of 48.99 and a beta of 0.98. The stock’s 50-day moving average price is $21.33 and its 200-day moving average price is $21.04. Grifols, S.A. has a 1-year low of $14.33 and a 1-year high of $23.32.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/10/31/beck-mack-oliver-llc-lowers-position-in-grifols-s-a-grfs.html.
A number of analysts recently weighed in on the stock. BidaskClub lowered shares of Grifols, from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Zacks Investment Research raised shares of Grifols, from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, July 4th. Citigroup Inc. assumed coverage on shares of Grifols, in a research note on Tuesday. They issued a “buy” rating for the company. Finally, Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $24.00.
Grifols, Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS).
What are top analysts saying about Grifols S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols S.A. and related companies.